LetigenĀ® and Cardiovascular Morbidity


Phase 4 Results N/A

Summary of Purpose

LetigenĀ® was a combination drug containing ephedrine, an adrenergic agonist with lipolytic and appetite-inhibiting properties. The drug was used as adjuvant treatment of obesity from 1990 and up to 2002 when it was withdrawn from the market by the manufacturer. The basis for this was a number of spontaneous reports about patients that died during treatment with LetigenĀ®. The causal relation has never been...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 5 June 2008.

1 May 2006 3 Jun 2008 1 May 2006 1 Aug 2007 1 Jun 2008 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Perspective: Retrospective


Not available